Abstract
OBJECTIVE--To investigate the value of measuring maternal urea resistant neutrophil alkaline phosphatase activity as an antenatal screening test for Down's syndrome. DESIGN--Case-control study of blood samples collected at nine to 27 weeks of pregnancy. SETTING--Antenatal clinics in London and Oxford. PATIENTS--72 Women whose fetuses had been diagnosed by amniocentesis or chorionic villus sampling as having Down's syndrome and 156 women whose fetuses did not have the syndrome. Only singleton pregnancies were studied. MAIN OUTCOME MEASURE--Activity of urea resistant neutrophil alkaline phosphatase measured cytochemically. RESULTS--The median enzyme activity in the index patients was 1.65 times the expected median for the controls at the same duration of pregnancy (p less than 0.0001; 95% confidence interval 1.56 to 1.74). A cut off value that identified the 5% of control patients with the highest activities yielded a rate of detection of Down's syndrome of 79% (95% confidence interval 70 to 89%). CONCLUSION--Activity of urea resistant neutrophil alkaline phosphatase is an effective maternal blood marker for Down's syndrome. Its use in antenatal screening could lead to a substantial improvement in the detection of this disorder. Before introducing the test into routine medical practice it will have to be automated so that it can be used on a large scale and is less subjective.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bartels I., Lindemann A. Maternal levels of pregnancy-specific beta 1-glycoprotein (SP-1) are elevated in pregnancies affected by Down's syndrome. Hum Genet. 1988 Sep;80(1):46–48. doi: 10.1007/BF00451454. [DOI] [PubMed] [Google Scholar]
- Cuckle H. S., Wald N. J., Densem J. W., Royston P., Knight G. J., Haddow J. E., Palomaki G. E. The effect of smoking in pregnancy on maternal serum alpha-fetoprotein, unconjugated oestriol, human chorionic gonadotrophin, progesterone and dehydroepiandrosterone sulphate levels. Br J Obstet Gynaecol. 1990 Mar;97(3):272–274. doi: 10.1111/j.1471-0528.1990.tb01794.x. [DOI] [PubMed] [Google Scholar]
- Grozdea J., Maret A., Vergnes H., Bourrouillou G., Verdier J., Martin J., Salvayre R., Colombies P. Cytochemical and biochemical studies on neutrophil alkaline phosphatase in parents of trisomy 21 children. Hum Genet. 1984;67(3):313–316. doi: 10.1007/BF00291360. [DOI] [PubMed] [Google Scholar]
- Grozdea J., Vergnes H., Martin J. Urea-resistant neutrophil alkaline phosphatase in mothers with trisomy 21 pregnancy. Lancet. 1983 Oct 1;2(8353):799–800. doi: 10.1016/s0140-6736(83)92338-3. [DOI] [PubMed] [Google Scholar]
- Wald N. J., Cuckle H. S., Densem J. W., Nanchahal K., Royston P., Chard T., Haddow J. E., Knight G. J., Palomaki G. E., Canick J. A. Maternal serum screening for Down's syndrome in early pregnancy. BMJ. 1988 Oct 8;297(6653):883–887. doi: 10.1136/bmj.297.6653.883. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wald N., Cuckle H., Densem J. Maternal serum specific beta 1-glycoprotein in pregnancies associated with Down's syndrome. Lancet. 1989 Aug 19;2(8660):450–450. doi: 10.1016/s0140-6736(89)90628-4. [DOI] [PubMed] [Google Scholar]